Compare PEG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEG | ALNY |
|---|---|---|
| Founded | 1903 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 42.1B |
| IPO Year | 1994 | 2004 |
| Metric | PEG | ALNY |
|---|---|---|
| Price | $83.19 | $322.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 28 |
| Target Price | $92.32 | ★ $471.93 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | 19.21 | ★ 206.88 |
| EPS | ★ 4.22 | 2.33 |
| Revenue | ★ $12,168,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $4.69 | $52.99 |
| Revenue Next Year | $4.22 | $31.77 |
| P/E Ratio | ★ $19.89 | $137.81 |
| Revenue Growth | 18.25 | ★ 22.88 |
| 52 Week Low | $76.74 | $225.84 |
| 52 Week High | $91.26 | $495.55 |
| Indicator | PEG | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 49.11 |
| Support Level | $80.11 | $302.52 |
| Resistance Level | $83.97 | $330.33 |
| Average True Range (ATR) | 1.34 | 10.91 |
| MACD | 0.30 | 1.16 |
| Stochastic Oscillator | 75.96 | 62.72 |
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.